With IP-10 serum and urine levels established in SLE/LN activity and healthy controls in these reports, the objectives of our LN-focused studies were to determine if IP-10 levels decrease with LN remission from patient follow-up, correlate with specific LN pathology, are different between LN and non-LN forms of GD, and to evaluate if there are differences between White and African American patients. Here, CXCL10 is linked to systemic lupus erythematosus.